Recommendation ID
NG191/1
Question

What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

Any explanatory notes
(if applicable)

Suggested PICO (Population, Intervention, Comparator, Outcome)

P: patients 16 years and over being treated for COVID-19 pneumonia in hospital or the community
who have:
• no additional risk factors for VTE
• additional risk factors for VTE

I: intermediate dose:
• low molecular weight heparins (LMWH)
• unfractionated heparin (UFH)
• fondaparinux sodium
• direct-acting anticoagulant
• vitamin K antagonists

C: standard-dose:
• LMWH UFH
• fondaparinux sodium
• direct-acting anticoagulants vitamin K antagonists antiplatelets

O:
• incidence of VTE
• mortality (all-cause, inpatient, COVID-19 related)
• admission to critical care (including use of advanced organ support)
• serious adverse events such as major bleeding or admission to hospital

Source guidance details

Comes from guidance
COVID-19 rapid guideline: managing COVID-19
Number
NG191
Date issued
March 2021

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 30/06/2021